Thymidylate synthase polymorphisms and mRNA expression are independent chemotherapy predictive markers in esophageal adenocarcinoma patients

International Journal of Oncology

Volumn 32, Issue 1, 2008, Pages 201-208

  Kuramochil, Hidekazu ^a,e   Tanaka, Koji ^a   Oh, Daniel ^b   Lehman, Bethany J ^b   Dunst, Christy M ^b   Yang, Dong Yun ^c   de Meester, Steven R ^b   Hagen, Jeffery A ^b   Danenberg, Kathleen D ^d   de Meester, Tom R ^b   Danenberg, Peter V ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d Response Genetics Inc   (United States)

^e TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Chemotherapy; Esophageal adenocarcinoma; Gene expression; Polymorphism; Thymidylate synthase

Indexed keywords

FLUOROURACIL; GENOMIC DNA; MESSENGER RNA; THYMIDYLATE SYNTHASE;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; DRUG RESPONSE; ENZYME ANALYSIS; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS RESECTION; FEMALE; GENE EXPRESSION; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PATIENT CODING; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

3' UNTRANSLATED REGIONS; 5' UNTRANSLATED REGIONS; ADENOCARCINOMA; ADULT; AGED; ESOPHAGEAL NEOPLASMS; FEMALE; GENOTYPE; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROGNOSIS; RNA, MESSENGER; THYMIDYLATE SYNTHASE;

EID: 38749114233     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Spechler SJ and Goyal RK: The columnar-lined esophagus, intestinal metaplasia and Norman Barrett. Gastroenterology 110: 614-621, 1996.
2. Brenner B, Ilson DH and Minsky BD: Treatment of localized esophageal cancer. Semin Oncol 31: 554-565, 2004.
3. Kelsen D: Preoperative chemoradiotherapy for esophageal cancer. J Clin Oncol 19: 283-285, 2001.
4. Mooney MM: Neoadjuvant and adjuvant chemotherapy for esophageal adenocarcinoma. J Surg Oncol 92: 230-238, 2005.
5. Leichman CG, Lenz HJ, Leichman L, et al: Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 15: 3223-3229, 1997.
6. Lenz HJ, Danenberg KD, Leichman CG, et al: p53 and thymidylate synthase expression in untreated stage II colon cancer: associations with recurrence, survival and site. Clin Cancer Res 4: 1227-1234, 1998.
7. Lenz HJ, Hayashi K, Salonga D, et al: p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. Clin Cancer Res 4: 1243-1250, 1998.
8. Salonga D, Danenberg KD, Johnson M, et al: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase and thymidine phosphorylase. Clin Cancer Res 6: 1322-1327, 2000.
9. Kaneda S, Takeishi K, Ayusawa D, Shimizu K, Seno T and Altman S: Role in translation of a triple tandemly repeated sequence in the 5′-untranslated region of human thymidylate synthase mRNA. Nucleic Acids Res 15: 1259-1270, 1987.
10. Kawakami K, Omura K, Kanehira E and Watanabe Y: Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. Anticancer Res 19: 3249-3252, 1999.
11. Ishida Y, Kawakami K, Tanaka Y, Kanehira E, Omura K and Watanabe G: Association of thymidylate synthase gene polymorphism with its mRNA and protein expression and with prognosis in gastric cancer. Anticancer Res 22: 2805-2809, 2002.
12. Pullarkat ST, Stoehlmacher J, Ghaderi V, et al: Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 1: 65-70, 2001.
13. Uchida K, Hayashi K, Kawakami K, et al: Loss of heterozygosity at the thymidylate synthase (TS) locus on chromosome 18 affects tumor response and survival in individuals heterozygous for a 28-bp polymorphism in the TS gene. Clin Cancer Res 10: 433-439, 2004.
14. Kawakami K and Watanabe G: Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. Cancer Res 63: 6004-6007, 2003.
15. Mandola MV, Stoehlmacher J, Muller-Weeks S, Cesarone G, Yu MC, Lenz HJ and Ladner RD: A novel single nucleotide polymorphism within the 5′ tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res 63: 2898-2904, 2003.
16. Ulrich CM, Bigler J, Velicer CM, Greene EA, Farin FM and Potter JD: Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene. Cancer Epidemiol Biomarkers Prev 9: 1381-1385, 2000.
17. Mandola MV, Stoehlmacher J, Zhang W, et al: A 6-bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics 14:319-327, 2004.
18. Stoehlmacher J, Park DJ, Zhang W, Yang D, Groshen S, Zahedy S and Lenz HJ: A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 91: 344-354, 2004.
19. Hitre E, Budai B, Adleff V, et al: Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil. Pharmacogenet Genomics 15: 723-730, 2005.
20. Liao Z, Liu H, Swisher SG, et al: Polymorphism at the 3′-UTR of the thymidylate synthase gene: a potential predictor for outcomes in Caucasian patients with esophageal adenocarcinoma treated with preoperative chemoradiation. Int J Rotor Oncol Biol Phys 3: 700-708, 2006.
21. Krajinovic M, Costea I, Primeau M, Dulucq S and Moghrabi A: Combining several polymorphisms of thymidylate synthase gene for pharmacogenetic analysis. Pharmacogenomics J 5: 374-380, 2005.
22. Lecomte T, Ferraz JM, Zinzindohoue F, et al: Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin Cancer Res 10: 5880-5888, 2004.
23. Kuramochi H, Hayashi K, Uchida K, et al: Vascular endothelial growth factor messenger RNA expression level is preserved in liver metastases compared with corresponding primary colorectal cancer. Clin Cancer Res 12: 29-33, 2006.
24. Lord RV, Salonga D, Danenberg KD, et al: Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence. J Gastrointest Surg 4: 135-142, 2000.
25. Kuramochi H, Hayashi K, Uchida K, et al: 5-fluorouracil-related gene expression levels in primary colorectal cancer and corresponding liver metastasis. Int J Cancer 119: 522-526, 2006.
26. Marcuello E, Altes A, Del Rio E, Cesar A, Menoyo A and Baiget M: Single nucleotide polymorphism in the 5′ tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients. Int J Cancer 112: 733-737, 2004.
27. Kawakami K, Graziano F, Watanabe G, et al: Prognostic role of thymidylate synthase polymorphisms in gastric cancer patients treated with surgery and adjuvant chemotherapy. Clin Cancer Res 11: 3778-3783, 2005.
28. Ruzzo A, Graziano F, Kawakami K, et al: Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. J Clin Oncol 24: 1883-1891, 2006.
29. Morganti M, Ciantelli M, Giglioni B, et al: Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancers. Eur J Cancer 41: 2176-2183, 2005.
30. Park JG, Collins JM, Gazdar AF, Allegra CJ, Steinberg SM, Greene RF and Kramer BS: Enhancement of fluorinated pyrimidine-induced cytotoxicity by leucovorin in human colorectal carcinoma cell lines. J Natl Cancer Inst 80: 1560-1564, 1988.
31. Sohn KJ, Croxford R, Yates Z, Lucock M and Kim YI: Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. J Natl Cancer Inst 96: 134-144, 2004.
32. Ukich CM, Curtin K, Potter JD, Bigler J, Caan B and Slattery ML: Polymorphisms in the reduced folate carrier, thymidylate synthase, or methionine synthase and risk of colon cancer. Cancer Epidemiol Biomarkers Prev 14: 2509-2516, 2005.
33. Chen J, Kyte C, Chan W, Wetmur JG, Fuchs CS and Giovannucci E: Polymorphism in the thymidylate synthase promoter enhancer region and risk of colorectal adenomas. Cancer Epidemiol Biomarkers Prev 13: 2247-2250, 2004.
34. Trinh BN, Ong CN, Coetzee GA, Yu MC and Laird PW: Thymidylate synthase: a novel genetic determinant of plasma homocysteine and folate levels. Hum Genet 111: 299-302, 2002.
35. Aschele C, Debernardis D, Casazza S, et al: Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. J Clin Oncol 17: 1760-1770, 1999.
36. Clark JL, Berger SH, Mittelman A and Berger FG: Thymidylate synthase gene amplification in a colon tumor resistant to fluoropyrimidine chemotherapy. Cancer Treat Rep 71:261-265, 1987.
37. Johnston PG, Fisher ER, Rockette HE, et al: The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 12: 2640-2647, 1994.
38. Edler D, Glimelius B, Hallstrom M, et al: Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol 20: 1721-1728, 2002.
39. Ahlgren JD: Thymidylate synthase in nodal metastases: prognostic for chemosensitivity but not for adjuvant therapy? J Clin Oncol 23: 5452-5454, 2005.
40. Popat S, Wort R and Houlston RS: Relationship between thymidylate synthase (TS) genotype and TS expression: a tissue microarray analysis of colorectal cancers. Int J Surg Pathol 13: 127-133, 2005.
41. Voeller D, Rahman L and Zajac-Kaye M: Elevated levels of thymidylate synthase linked to neoplastic transformation of mammalian cells. Cell Cycle 3: 1005-1007, 2004.
42. Rahman L, Voeller D, Rahman M, et al: Thymidylate synthase as an oncogene: a novel role for an essential DNA synthesis enzyme. Cancer Cell 5: 341-351, 2004.
43. Vogelstein B, Fearon ER, Kern SE, Hamilton SR, Preisinger AC, Nakamura Y and White R: Allelotype of colorectal carcinomas. Science 244: 207-211, 1989.
44. Kawakami K, Ishida Y, Danenberg KD, Omura K, Watanabe G and Danenberg PV: Functional polymorphism of the thymidylate synthase gene in colorectal cancer accompanied by frequent loss of heterozygosity. Jpn J Cancer Res 93: 1221-1229, 2002.
45. Adleff V, Hitre E, Koves I, Orosz Z, Hajnal A and Kralovanszky J: Heterozygote deficiency in thymidylate synthase enhancer region polymorphism genotype distribution in Hungarian colorectal cancer patients. Int J Cancer 108: 852-856, 2004.
46. Graziano F, Kawakami K, Watanabe G, et al: Association of thymidylate synthase polymorphisms with gastric cancer susceptibility. Int J Cancer 112: 1010-1014, 2004.